Abstract Prostate cancer is one of the most prevalent forms of cancer around the world. Androgen-deprivation treatment and chemotherapy are the curative approaches used to suppress prostate cancer progression. However, drug resistance is extensively and hard to overcome even though remarkable progress has been made in recent decades. Noncoding RNAs, such as miRNAs, lncRNAs, and circRNAs, are a group of cellular RNAs which participate in various cellular processes and diseases. Recently, accumulating evidence has highlighted the vital role of non-coding RNA in the development of drug resistance in prostate cancer. In this review, we summarize the important roles of these three classes of noncoding RNA in drug resistance and the potential the...
Prostate cancer (PCa) is the most common type of cancer and the second leading cause of cancer-relat...
Sarcomas are a group of malignant tumors that arise from mesenchymal origin. Despite significant dev...
Sarcomas are a group of malignant tumors that arise from mesenchymal origin. Despite significant dev...
Although several therapeutic options have been shown to improve survival of most patients with prost...
Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progresses to a b...
Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progresses to a b...
The treatment landscape of prostate cancer has evolved rapidly over the past five years. The explosi...
[[abstract]]Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progr...
[[abstract]]Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progr...
Prostate cancer is the second most common cause of cancer mortality among men in the United States. ...
Prostate cancer is considered the second most common visceral malignancy in men in Western countries...
Prostate cancer (PCa) is a major health issue in the Western world. Current clinical imperatives for...
Cancer is an important health issue worldwide. Cancer therapy is multifaceted, and drug resistance i...
Abstract Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Recent adva...
Prostate cancer (PCa) is the most common type of cancer and the second leading cause of cancer-relat...
Prostate cancer (PCa) is the most common type of cancer and the second leading cause of cancer-relat...
Sarcomas are a group of malignant tumors that arise from mesenchymal origin. Despite significant dev...
Sarcomas are a group of malignant tumors that arise from mesenchymal origin. Despite significant dev...
Although several therapeutic options have been shown to improve survival of most patients with prost...
Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progresses to a b...
Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progresses to a b...
The treatment landscape of prostate cancer has evolved rapidly over the past five years. The explosi...
[[abstract]]Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progr...
[[abstract]]Hormone-refractory prostate cancer frequently relapses from therapy and inevitably progr...
Prostate cancer is the second most common cause of cancer mortality among men in the United States. ...
Prostate cancer is considered the second most common visceral malignancy in men in Western countries...
Prostate cancer (PCa) is a major health issue in the Western world. Current clinical imperatives for...
Cancer is an important health issue worldwide. Cancer therapy is multifaceted, and drug resistance i...
Abstract Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Recent adva...
Prostate cancer (PCa) is the most common type of cancer and the second leading cause of cancer-relat...
Prostate cancer (PCa) is the most common type of cancer and the second leading cause of cancer-relat...
Sarcomas are a group of malignant tumors that arise from mesenchymal origin. Despite significant dev...
Sarcomas are a group of malignant tumors that arise from mesenchymal origin. Despite significant dev...